At the news
? NEUTRALIMPACT 2/10 DEFA14A filed Mar 27, 2026 at 16:30 ET
Ultragenyx Pharmaceutical Inc. (RARE) has filed a definitive additional proxy soliciting material (DEFA14A) for its 2026 Annual Meeting. The filing is routine and contains standard voting instructions for shareholders, including a notice to vote on proposals by May 13, 2026, and information on how to access meeting materials. There is no material financial data or significant corporate action disclosed.
- Filing is a DEFA14A, which is a definitive additional proxy soliciting material.
- It is for the 2026 Annual Meeting of shareholders.
- The document contains a notice to vote by May 13, 2026, and instructions on how to access the proxy statement and annual report.
- The filing is routine and does not contain any new financial information or significant corporate announcements.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access